Manila Bulletin
China’s Sinovac applies for EUA for COVID vaccine
Chinese pharmaceutical company Sinovac has submitted an application for emergency use authorization (EUA) to the Philippine Food and Drug Administration (FDA).
FDA Director General Eric Domingo stated that Sinovac has not yet completed the submission of all necessary requirements for an EUA.
Specifically, the company has only submitted Phase 1 and Phase 2 clinical trial results, and Phase 3 human trial results are still needed to assess the vaccine's benefits and risks.
The efficacy of Sinovac's vaccine has varied in different trial locations, showing 50% in Brazil, 65% in Indonesia, and 91% in Turkey.
The Philippines aims to secure 25 million doses of the Sinovac vaccine in the first quarter of the year.
Sinovac has already received EUA in China and Indonesia.
Topics in this story
Explore more stories about these topics.
🤖
This story was generated by AI to help you understand the key points. For more detailed coverage, please see the news articles from trusted media outlets below.
News Sources
See how different news organizations are covering this story. Below are the original articles from various Philippine news sources that contributed to this summary.
The Food and Drug Administration (FDA) has approved Sinovac Biotech's application to conduct clinical trials for its COVID-19 vaccine in the Philippines.
Read more →
The Philippine FDA has approved Clover Biopharmaceuticals' application for Phase III clinical trials of its COVID-19 vaccine in the country.
Read more →
The Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) to the Pfizer-BioNTech COVID-19 vaccine, making it the first to receive such approval in the country.
+2
Read more →
Russia's Gamaleya Research Institute has applied for an emergency use authorization (EUA) for its Sputnik V vaccine in the Philippines.
Read more →
The Philippines has secured 25 million doses of the COVID-19 vaccine from the Chinese firm Sinovac, with the first batch expected in February.
Read more →